open access

Vol 75, No 4 (2017)
Original articles
Published online: 2016-12-27
Submitted: 2016-08-05
Accepted: 2016-11-14
Get Citation

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Hamdi Pusuroglu, Umut Somuncu, Ismail Bolat, Ozgur Akgul, Vesile Ornek, Hayriye Ak Yıldırım, Emre Akkaya, Huseyin Karakurt, Aydın Yıldırım, Ayfer Utku Savaş
DOI: 10.5603/KP.a2016.0185
·
Kardiol Pol 2017;75(4):351-359.

open access

Vol 75, No 4 (2017)
Original articles
Published online: 2016-12-27
Submitted: 2016-08-05
Accepted: 2016-11-14

Abstract

Background: Obstructive sleep apnoea syndrome (OSAS) is reported to be associated with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling. A significant relationship between galectin-3 and the total number of coronary plaques and the macrocalcified plaque structures of patients with type 2 diabetes mellitus has been reported.

Aim: The aim of this study was to investigate the association between galectin-3 level and coronary plaque burden as well as OSAS severity in patients with OSAS.

Methods: A total of 87 consecutive patients with a diagnosis of OSAS and 21 age- and gender-matched control subjects were recruited for the present study. The patients with OSAS were also categorised according to their apnoea hypopnoea index (AHI) as follows: mild (AHI = 5–15), moderate (AHI = 15–30), and severe (AHI > 30). All study subjects underwent coronary computed tomography angiography to detect coronary atherosclerosis. Also, all participants of serum galectin-3 concentrations were measured.

Results: Mean galectin-3 level was significantly higher in patients with OSAS compared to control subjects (p < 0.001) and in the severe OSAS group, compared to the moderate and mild OSAS groups (p < 0.001). Correlation analysis indicated significant positive relationships between galectin-3 concentrations and the total number of coronary plaques (p < 0.001), high-sensitivity C-reactive protein (p = 0.001), and severity of OSAS (p < 0.001). In multivariate analysis, galectin-3 (p = 0.01) and age (p = 0.025) were significant independent predictors of coronary atherosclerosis, after adjusting for other risk factors. Also, it has been found that galectin-3 concentration is a predictor of OSAS severity (p = 0.001).

Conclusions: Galectin-3 is associated with coronary atherosclerosis and OSAS severity in OSAS patients.

Abstract

Background: Obstructive sleep apnoea syndrome (OSAS) is reported to be associated with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling. A significant relationship between galectin-3 and the total number of coronary plaques and the macrocalcified plaque structures of patients with type 2 diabetes mellitus has been reported.

Aim: The aim of this study was to investigate the association between galectin-3 level and coronary plaque burden as well as OSAS severity in patients with OSAS.

Methods: A total of 87 consecutive patients with a diagnosis of OSAS and 21 age- and gender-matched control subjects were recruited for the present study. The patients with OSAS were also categorised according to their apnoea hypopnoea index (AHI) as follows: mild (AHI = 5–15), moderate (AHI = 15–30), and severe (AHI > 30). All study subjects underwent coronary computed tomography angiography to detect coronary atherosclerosis. Also, all participants of serum galectin-3 concentrations were measured.

Results: Mean galectin-3 level was significantly higher in patients with OSAS compared to control subjects (p < 0.001) and in the severe OSAS group, compared to the moderate and mild OSAS groups (p < 0.001). Correlation analysis indicated significant positive relationships between galectin-3 concentrations and the total number of coronary plaques (p < 0.001), high-sensitivity C-reactive protein (p = 0.001), and severity of OSAS (p < 0.001). In multivariate analysis, galectin-3 (p = 0.01) and age (p = 0.025) were significant independent predictors of coronary atherosclerosis, after adjusting for other risk factors. Also, it has been found that galectin-3 concentration is a predictor of OSAS severity (p = 0.001).

Conclusions: Galectin-3 is associated with coronary atherosclerosis and OSAS severity in OSAS patients.

Get Citation

Keywords

galectin-3, obstructive sleep apnoea syndrome, coronary atherosclerosis

About this article
Title

Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 75, No 4 (2017)

Pages

351-359

Published online

2016-12-27

DOI

10.5603/KP.a2016.0185

Bibliographic record

Kardiol Pol 2017;75(4):351-359.

Keywords

galectin-3
obstructive sleep apnoea syndrome
coronary atherosclerosis

Authors

Hamdi Pusuroglu
Umut Somuncu
Ismail Bolat
Ozgur Akgul
Vesile Ornek
Hayriye Ak Yıldırım
Emre Akkaya
Huseyin Karakurt
Aydın Yıldırım
Ayfer Utku Savaş

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl